摘要
目的:评价中药治疗胃癌癌前病变的临床疗效。方法:搜索单纯中药与西药对照治疗胃癌癌前病变的随机对照试验,对纳入研究的试验质量进行方法学评价,并用Cochrane协作网专用软件RevMan4.2进行Meta分析。结果:有16篇随机对照试验共治疗1714名病人满足纳入标准,试验均在中国进行。与西药对照组相比,中药对胃癌癌前病变患者的胃镜、萎缩、肠化、异型增生、HP改善情况及综合疗效有优势,合并RR、95%可信区间(CI)及P值分别为〔RR1.51,95%CI(1.42,1.62),P<0.00001〕、〔RR1.34,95%CI(1.16,1.54),P<0.0001〕、〔RR1.85,95%CI(1.57,2.19),P<0.00001〕、〔RR1.77,95%CI(1.42,2.21),P<0.00001〕,〔RR2.19,95%CI(1.66,2.88),P<0.00001〕、〔RR1.90,95%CI(1.60,2.27),P<0.00001〕。结论:中药治疗胃癌癌前病变有较好的疗效,但由于纳入研究的质量偏低,仍须科学设计临床研究方案,进行严格的、多中心、大样本的随机双盲对照试验,以提供更具说服力的证据。
Objective：To assess the effectiveness of traditional Chinese Herbal Medicine for PLGC. Methods：All the papers concerning PLGC treated by purely Chinese Herbal Medieine intervention and controlled with western medicine intervention were collected. Meta-analysis was performed by using the statistical software RevMan4.2.Results： 16 RCTs, including 1714 patients accord with criteria, and these trials were all made in china. Compared with western medicine, Chinese Herbal Medicine are more effective in improving the patients, endoscopy, atrophic, intestinal metaplasia, atypical hyperplasia and overall effect, [ RR1.51,95% CI （1.42,1.62）, P〈0.00001 3, [ RR 1.34,95% CI （1.16,1.54）, P〈0.0001 ], RR1.85,95% CI （1.57,2.19）, P〈0.00001] RR 1.77,95% CI （1.42,2.21）, P〈0.00001 3, [ RR2.19,95% CI （1.66,2.88）, P〈0.00001 ], [ RR1.90,95 % CI （1.60,2.27）, P〈0.00001 3. Conclusion： The therapeutic effect of Chinese Herbal Medicine intervention therapy of PLGC was assured, but the evidence of a large, muhieenter, randomized controlled trials are urgently needed so as to provide more convincible evidence.
出处
《辽宁中医药大学学报》
CAS
2009年第11期35-37,共3页
Journal of Liaoning University of Traditional Chinese Medicine
关键词
中药
胃癌癌前病变
随机对照试验
荟萃分析
Chinese Herb
Precancerous lesions of gastric cancer
randomized controlled trials
Metaanalysis
